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Brief Clinical Reportsbreath and wheezing. Indeed, it could have been an en-
tirely coincidental series of events that led to the identifi-
cation and removal of the pacing wire. The significance
of this event is in the fact that this wire was found in the
right ventricle and pulmonary artery after its placement
in the epicardium after coronary artery bypass grafting
24 years previously.
Several case reports have been published pertaining to
complications from retained epicardial wire migration.
Korompai and colleagues3 first reported a case of migrated
temporary pacing wire found in the peritoneal cavity in
1987, thought to be retained after cardiac surgery that had
been performed 6 years previously. Three years after sur-
gery, Meier and colleagues4 reported a case of ventricular
tachycardia and cardiac arrest associated with erosion of
an epicardial pacing wire through the right atrium. Juchem
and colleagues5 reported a patient who had undergone mi-
tral valve replacement 2 years previously; aortic and mitral
prosthetic valve endocarditis developed secondary to in-
fected pacing wire coursing from the aortic bulb to the right
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Migration is a well-established albeit rare complication
of retained temporary pacing wires, with a variety of clini-
cal effects. The exact mechanism as to how the wire dis-
lodged into the heart is unknown, but it may be a result of
constant movement of the heart and diaphragm. We de-
scribe the most remote complication of retained pacer wires
to date, diagnosed 24 years from placement. The retention
of cardiac pacing wires should be communicated to all phy-
sicians responsible for the patient’s care because it could
lead to issues many decades after surgery.
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to support a patient with a failing Fontan circulationDavidL. S.Morales,MD, IkiAdachi,MD, Jeffrey S.Heinle,MD, andCharlesD. Fraser, Jr,MD,Houston,TexWorldwide experiencewithventricular assist device (VAD)
support in patients with univentricular physiology has been
very limited. In particular, the use of a long-term continu-
ous-flow implantable VAD has never been described. We
report the successful application of an intracorporeal systemic
ventricular assist device (SVAD), the HeartMate II (Thoratec
Corporation, Pleasanton,Calif), in anadolescentwitha failing
Fontan circulation and protein-losing enteropathy (PLE).CLINICAL SUMMARY
The patient is a 15-year-old boy (body surface area,
1.5 m2) with double-outlet right ventricle, mitral atresia,and a systemic right ventricle. He underwent staged pallia-
tion culminating in a fenestrated lateral Fontan operation at
3 years old. Although he did well for many years, his con-
dition began to deteriorate with increasing dyspnea on exer-
tion, peripheral pitting edema, and hepatomegaly with
ascites. PLE was diagnosed (serum albumin, 2.6 g/dL; pre-
albumin, 9.7 mg/dL). Echocardiogram revealed severely
depressed systolic ventricular function with significant tri-
cuspid regurgitation. In preparation for cardiac transplanta-
tion, a cardiac catheterization was performed. After
induction of positive-pressure ventilation, he had several
periods of cardiac arrest necessitating resuscitation. The ab-
breviated catheterization demonstrated a severely elevated
Fontan pressure of 30 mm Hg, a pulmonary vascular resis-
tance of 1.9 Wood units, normal caliber pulmonary arteries,
and a wedge pressure of 22 mmHg. Because his circulatory
failure was primarily the result of systemic ventricular dys-
function and his condition was hemodynamically unstable,
he underwent urgent VAD placement.
Because the patient had levocardia with normally related
great arteries, a HeartMate II SVAD was implanted in the
usual manner (Figure 1) on cardiopulmonary bypass with-
out cardiac arrest. The only atypical aspect was thegery c September 2011
FIGURE 1. Preoperative and postoperative chest x-ray films.
Brief Clinical Reportsnecessity of closing the Fontan fenestration to prevent post-
operative cyanosis and aggressively resecting coarse apical
right ventricular trabeculations when placing the inflow
cannula. After bypass, transesophageal echocardiography
demonstrated adequate positioning of the cannulas and
good right ventricular decompression with the patient re-
ceiving inhaled nitric oxide and nicardipene only.
The patient was in hemodynamically stable condition
throughout the postoperative period with a central venous
pressure thatwas 10mmHgafter extubation onpostoperative
day 7. The HeartMate II SVAD was programmed at higher
than normal revolutions per minute to ensure complete de-
compression of the systemic ventricle because pulmonary
blood flow was passive (Table 1). Using aspirin and warfarin
sodium (target international normalized ratio of 2.0), there
were no thrombotic complications. His exercise tolerance
improved significantly, and at 2 months postoperatively he
had no heart failure symptoms and the PLE clinically and
chemically resolved (albumin, 4.0 g/dL; prealbumin, 12.0TABLE 1. Hemodynamic and device parameters
One day
before operation
One
after op
Device parameters
Flow (L/min) — 5.
Speed (rpm) — 92
Pump power (W) — 5.
Pulsatile index — 3.
Hemodynamic parameters
Inotropes/vasodilators Epinephrine 0.1
mg $ kg1 $ min1,
CaCl 10 mg $ kg1 $ h,
vasopressin 0.2
units $ kg1 $ h
Nicardip
1.5 m
Respiratory support Intubated, FIO2 1.0 Intubate
FIO2 0
Arterial blood pressure (mm Hg) 98/58 (72) (7
Central venous pressure (mm Hg) 30 1
Atrial pressure (mm Hg) (22)* (8
Oxygen saturation (%) 85 9
Fio2, Forced expiratory volume in 1 second. *Estimated with a left pulmonary wedge pre
The Journal of Thoracic and Carmg/dL). The patient was discharged home and underwent
successful transplant at 72 days of support.
DISCUSSION
Implantation of a VAD to sustain the Fontan circulation
has been reported butmostly in the setting of short-term sup-
port using extracorporeal devices or long-term support with
paracorporeal devices.1-3 Frazier, Gregoric, and Messner1
did report the use of a pneumatic HeartMate IP LVAS (Thor-
atec Corp) in a Fontan patient who while recovering in the
hospital received a transplant at 45 days of support. In partic-
ular, the use of an implantable VAD in anticipation of long-
term support and discharging the patient home has not been
described. The chronic failure of a Fontan circulation ismul-
tifactorial and is not always primarily a systemic ventricular
problem.4 This may explain why successful VAD support of
the failing Fontan circulation has been inconsistent. There-
fore, careful consideration should be given to assess whether
systemic ventricular failure is the main cause of the failingday
eration
One day
before extubation
One day
after extubation
One day
before discharge
2 5.9 6.3 6.0
00 9400 9400 9400
4 5.8 6.4 7.1
6 3.7 4.2 4.1
ine
g/h
Nicardipine
1.0 mg/h
— —
d,
.4
Intubated,
FIO2 0.4
Nasal cannula,
FIO2 1.0
Room air
5) (72) (84) (79)
5 15 11 —
)* — — —
3 95 95 92
ssure.
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Brief Clinical Reportscirculation. If it is, then an SVAD should improve the overall
circulation. However, if the left ventricular end-diastolic
pressure is not high, then an SVAD is unlikely to improve he-
modynamics. If the pulmonary circulation is primarily re-
sponsible for hemodynamic deterioration, then insertion of
a VAD at a subpulmonary position is an option.2 Much ani-
mal and computer modeling has been done to study the pos-
sibility of mechanically augmenting pulmonary blood flow
in the Fontan baffle.5
The lack of a subpulmonary ventricle in the Fontan phys-
iology may result in suboptimal filling of an SVAD. There-
fore, we believe that it is important to ensure almost
complete systemic ventricular decompression by setting
the HeartMate II SVAD at higher revolutions per minute
to encourage passive flow into the pulmonary arteries.
Also, with a single ventricle, unlike in a biventricular heart,
there is little concern, even at high revolutions per minute,
of jeopardizing output of the pulmonary ventricle by shift-
ing of the intraventricular septum. With these settings, cen-
tral venous pressure decreased significantly with adequate
systemic blood pressure (Table 1), yielding reasonableFrom the Section of Cardiac Surgery, University of Michigan Health System, Ann
Arbor, Mich.
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uted to the improvement in his PLE.
This is the first report of successfully discharging home
a patient who has a failing Fontan circulation with an im-
plantable VAD. Given the increasing cohort of adults and
children with failing Fontan circulations, this case repre-
sents a significant evolution in therapy for single ventricle
patients who will increasingly be receiving SVADs not
only for support to transplant but also perhaps to destination.References
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Thorac Surg. 2009;88:170-6.The use of the HeartWare HVAD for long-term right ventricular
support after implantation of the HeartMate II deviceJohn M. Stulak, MD, Kevin E. Griffith, John M. Nicklas, MD, and Francis D. Pagani, MD, PhD,
Ann Arbor, MichBiventricular support is required in approximately 6%
to 30% of patients undergoing implantation of left ventric-
ular assist devices (LVADs).1 Although the routine applica-
tion of a reliable, long-term implantable right ventricular
assist device (RVAD) remains elusive, use of the Heart-
Ware HVAD (HeartWare International, Inc, Framingham,
Mass) and Jarvik 2000 (Jarvik Heart, Inc, New York,
NY) for long-term totally implantable biventricular
support has been reported.2,3 Although the only reports
in existence detail the use of 2 HeartWare HVADs forbiventricular support, we report the use of this device
for right ventricular support after implantation of
a HeartMate II LVAD (Thoratec Corporation, Pleasanton,
Calif).CLINICAL SUMMARY
A 59-year-old African American woman with nonische-
mic cardiomyopathy and congestive heart failure was seen
with acute, decompensated heart failure and rapidly deteri-
orating condition. After evaluation, the patient underwent
emergency HeartMate II and CentriMag RVAD (Thoratec)
implantation for biventricular failure. Postoperatively, the
patient had several failed attempts at RVAD weaning and
was subsequently listed status 1A for heart transplant. After
transplant workup, numerous antibodies with a high panel-
reactive antibody titer were noted, and the patient underwent
several rounds of plasmapheresis, intravenous immune
globulin, and bortezomib (Velcade). Despite these interven-
tions, transplant was essentially excluded as a result of
significant persistent allosensitization. An appeal was
subsequently made for compassionate use of the HeartWaregery c September 2011
